Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (NASDAQ: INVA), will present data from four abstracts at IDWeek 2026 in Washington, D.C., October 21-24. The presentations cover its two FDA-approved antibiotics, ceftobiprole (ZEVTERA) and zoliflodacin (NUZOLVENCE), including in vitro activity data, pediatric dosing work, and an oral presentation on zoliflodacin's efficacy in gonorrhea patients co-infected with chlamydia.
Key figures
- Drug Name
- ZEVTERA (ceftobiprole), NUZOLVENCE (zoliflodacin)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.